Effect of adding personalized instant messaging applications to brief smoking cessation model in community smokers: A pragmatic randomized clinical trial (Preprint)

Author:

Wu Yongda SocratesORCID,CHEUNG Yee Tak DerekORCID,LEE Jay Jung JaeORCID,WONG Carlos King HoORCID,HO Sai YinORCID,LI William Ho CheungORCID,YAO YingORCID,LAM Tai HingORCID,WANG Man PingORCID

Abstract

BACKGROUND

Text-messaging is effective for smoking cessation (SC).

OBJECTIVE

We assess if more interactive and adaptive instant messaging (IM) apps on a smartphone that allows personalization and chatting with SC advisors could further increase SC.

METHODS

700 adult Chinese daily cigarette users were proactively recruited in communities in Hong Kong from December 2018 to November 2019 and 1:1 randomized. All participants received face-to-face brief advice on SC, active referral (AR) to SC services at baseline. Intervention group received personalized regular messages and chatting through IM apps for 3 months, meanwhile control group received text messages on general health. The primary outcomes were smoking abstinence validated by carbon monoxide <4 parts per million at 6 and 12 months after intervention initiation. Trial Registry: ClinicalTrials.gov NCT03800719.

RESULTS

72.1% were male, 69.4% were aged 40 or above. At 6- and 12-month follow-up (retention rate: 65.1% and 63.7%), by intention to treat, validated quit rates were similar between the intervention (4.0% and 5.4%) and control (3.1% and 6.0%) groups. Self-reported 7-day point prevalence abstinence (9.1% vs 8.3%, 13.1% vs 14.3%) at both follow-ups were similar. Intervention group reported more SC service use at 12-month (35.1%) than control group (28.0%): adjusted risk ratio=1.26 (95% confidence interval 1.01-1.57).

CONCLUSIONS

An IM-based intervention providing support and assistance on top of brief SC advice and AR did not further increase quitting but promoted SC service use. Further studies can examine if increased SC service use result in better SC in a longer term.

CLINICALTRIAL

Trial Registry: ClinicalTrials.gov NCT03800719. ULR:https://beta.clinicaltrials.gov/study/NCT03800719

Publisher

JMIR Publications Inc.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3